Influenza vaccine effectiveness in Australia: Results from the Australian Sentinel Practices Research Network

Medical Journal of Australia

Volumn 201, Issue 2, 2014, Pages 109-111

  Sullivan, Sheena G ^a   Chilver, Monique B N ^b   Higgins, Geoff ^c   Cheng, Allen C ^d,e   Stocks, Nigel P ^b  

^a PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Microbiology and Infectious Diseases   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e Department of Infectious Diseases Alfred Health ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CHILD; CHILD, PRESCHOOL; FEMALE; GENERAL PRACTICE; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; MIDDLE AGED; SENTINEL SURVEILLANCE; VACCINATION; YOUNG ADULT;

EID: 84904655820     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja14.00106     Document Type: Article

References (17)

1. Surveillance systems reported in CDI, 2011. Commun Dis Intell Q Rep 2011; 35: 5 5-59.
2. Clothier HJ, Fielding JE, Kelly HA. An evaluation of the Australian Sentinel Practice Research Network (ASPREN) surveillance for Influenzalike illness. Commun Dis Intell Q Rep 2005; 29: 231-247.
3. Parrella A, Dalton CB, Pearce R, et al. ASPREN surveillance system for Influenza-like illness. A comparison with FluTracking and the National Notifiable Diseases Surveillance System. Aust Fam Physician 2009; 38: 932-936.
4. Jackson ML, Nelson JC. The test-negative design for estimating Influenza vaccine effectiveness. Vaccine 2013; 31: 2165-2168.
5. Orenstein EW, De Serres G, Haber MJ, et al. Methodologic issues regarding the use of three observational study designs to assess Influenza vaccine effectiveness. Int J Epidemiol 2007; 36: 623-631.
6. Skowronski D, Gilbert M, Tweed S, et al. Effectiveness of vaccine against medical consultation due to laboratory-confi rmed Influenza: results from a sentinel physician pilot project in British Columbia, 2004-2005. Can Commun Dis Rep 2005; 31: 181-191.
7. Kelly H, Grant K. Interim analysis of pandemic Influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 2009; 14. pii: 1 9288.
8. Kissling E, Valenciano M, Larrauri A, et al. Low and decreasing vaccine effectiveness against Influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill 2013; 18. p ii: 2 0390.
9. Pebody R, Andrews N, McMenamin J, et al. Vaccine effectiveness of 2011/12 trivalent seasonal Influenza vaccine in preventing laboratory-confirmed Influenza in primary care in the United Kingdom: evidence of waning intraseasonal protection. Euro Surveill 2013; 18. p ii: 2 0389.
10. Skowronski DM, Janjua NZ, Sabaiduc S, et al. Influenza A/subtype and B/ lineage effectiveness estimates for the 2011-12 trivalent vaccine: crossseason and cross-lineage protection with unchanged vaccine. J Infect Dis 2014; Apr 1 [Epub ahead of print].
11. Sullivan SG, Komadina N, Grant K, et al. Influenza vaccine effectiveness during the 2012 Influenza season in Victoria, Australia: Infl uences of waning immunity and vaccine match. J Med Virol 2014; 86: 1017-1025.
12. Tricco AC, Chit A, Soobiah C, et al. Comparing Influenza vaccine efficacy against mismatched and matched strains: a systematic review and metaanalysis. BMC Med 2013; 11: 153.
13. World Health Organization. WHO consultation and information meeting on the composition of Influenza virus vaccines for the southern hemisphere 2013. Geneva: World Health Organization, 2013. http://www.who.int/ Influenza/vaccines/virus/recommendations/consultation201209/en (accessed Mar 2013).
14. Castilla J, Martinez-Baz I, Martinez-Artola V, et al. Decline in Influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013; 18. p ii: 2 0388.
15. Valenciano M, Ciancio B, Moren A. First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic Influenza in EU/EEA member states. Euro Surveill 2008; 13. p ii: 1 9015.
16. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human Influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167: 775-785.
17. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of Influenza vaccine. Vaccine 2013; 31: 310 4-3109.